According to the WHO, dyslipidemias or hyperlipidemias are disorders of blood lipids characterized by an increase in cholesterol levels or hypercholesterolemia and/or increases in triglyceride (TG) concentrations called hypertriglyceridemia.
Dyslipidemia is one of the main cardiovascular risk factors through the appearance of arteriosclerosis.
Hepatic lipase produces structural and compositional changes in LDL, which become smaller and denser, with greater susceptibility to oxidation and lower affinity for binding to the LDL receptor and therefore remain in the circulation longer and tend to settle.
This leads to an increase in the uptake of LDL by the endothelium, its oxidation, deposition and accumulation in the vessel wall , with the consequent inflammatory and immune response.
Arteriosclerosis is a systemic disease that can affect all the arteries in the body. Initially, it may follow a subclinical course, and symptoms appear when an artery becomes severely narrowed. The symptoms will depend on the affected arterial territory: coronary, carotid, peripheral, and renal.
Prevalence of Dyslipidemia in our environment: between 31-50% of the general population in Spain has Dyslipidemia.
Being more common in patients with acute coronary events. On the other hand, in Spain Cardiovascular Disease is the most frequent cause of death ahead of Cancer.
What should new therapies provide?
- Significant reduction in LDL-c levels
- Blocking new steps in the cholesterol synthesis pathway
- Good tolerance
By Dr. Roberto Martín Reyes